| Grant ID | RP220410 |
| Awarded On | February 16, 2022 |
| Title | Mechanisms and therapies focused on epigenomic alterations in therapy-resistant prostate cancers |
| Program | Academic Research |
| Award Mechanism | Individual Investigator |
| Institution/Organization | The University of Texas M.D. Anderson Cancer Center |
| Principal Investigator/Program Director | Kunal Rai |
| Cancer Sites | Prostate |
| Contracted Amount | $1,049,532 |
| Lay Summary |
Prostate cancer related deaths usually occur due to metastatic spread and resistance to various therapies. Historically the median survival for men with advanced therapy-resistant prostate cancer has been less than two years. Whether epigenomic aberrations contribute to evolution of resistant clones in therapy-resistant aggressive prostate cancers is not well understood. In preliminary studies, we profiled various epigenomic elements in therapy-resistant human tumor samples and treatment-naive primary samples to define changes specific to resistant tumors. We found that H3K4me1 (a modification of histone proteins)-marked enhancer states are highly enriched in therapy-resistant samples which ... |